Share on StockTwits

PTC Therapeutics (NASDAQ:PTCT) CFO Shane William Charles Kovacs unloaded 1,650 shares of the company’s stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $14.74, for a total value of $24,321.00. Following the transaction, the chief financial officer now directly owns 12,350 shares in the company, valued at approximately $182,039. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

A number of analysts have recently weighed in on PTCT shares. Analysts at Credit Suisse raised their price target on shares of PTC Therapeutics from $35.00 to $40.00 in a research note on Friday. Separately, analysts at Zacks upgraded shares of PTC Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Thursday. They now have a $15.00 price target on the stock. Finally, analysts at Zacks downgraded shares of PTC Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 23rd. They now have a $19.70 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $30.92.

PTC Therapeutics (NASDAQ:PTCT) traded up 30.74% during mid-day trading on Friday, hitting $20.03. 10,198,147 shares of the company’s stock traded hands. PTC Therapeutics has a 52 week low of $1.563 and a 52 week high of $34.65. The stock’s 50-day moving average is $18.51 and its 200-day moving average is $21.81. The company’s market cap is $587.4 million.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.58) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.46) by $0.12. Analysts expect that PTC Therapeutics will post $-2.89 EPS for the current fiscal year.

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of orally administered, small-molecule drugs that target post-transcriptional control processes.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.